Atypical Cogan's syndrome: a case report and summary of current treatment options
Language English Country Ireland Media print-electronic
Document type Case Reports, Journal Article
PubMed
25600284
DOI
10.1016/j.ijporl.2014.12.028
PII: S0165-5876(14)00696-X
Knihovny.cz E-resources
- Keywords
- Cogan's syndrome, Corticosteroids, Immunosuppressive therapy, Interstitial keratitis, Sensorineural hearing loss, Vertigo,
- MeSH
- Azathioprine therapeutic use MeSH
- Cogan Syndrome diagnosis drug therapy MeSH
- Glucocorticoids therapeutic use MeSH
- Immunosuppressive Agents therapeutic use MeSH
- Humans MeSH
- Methylprednisolone therapeutic use MeSH
- Adolescent MeSH
- Nausea etiology MeSH
- Hearing Loss, Bilateral etiology MeSH
- Hearing Loss, Sensorineural etiology MeSH
- Vertigo etiology MeSH
- Vomiting etiology MeSH
- Check Tag
- Humans MeSH
- Adolescent MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Azathioprine MeSH
- Glucocorticoids MeSH
- Immunosuppressive Agents MeSH
- Methylprednisolone MeSH
Cogan's syndrome is a rare chronic vasculitis, characterized in its typical form by progressive sensorineural bilateral hearing loss, vestibular symptoms and non-syphilitic interstitial keratitis. Only a few cases have been reported in children, most of whom have been diagnosed with the typical form. Early diagnosis and treatment are crucial to ensure a favorable prognosis. Systemic treatment usually begins with high dosage corticosteroids. In case the initial treatment fails, other immunosuppressive drugs are used (cyclophosphamide, methotrexate, cyclosporine A and azathioprine). Additional treatment possibilities, such as plasmapheresis, TNF-alpha blockers (etanercept and infliximab), rituximab, tocilizumab and mycophenolate mofetil have been described over the past few years.
References provided by Crossref.org
